These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Fisler RE; Saeb M; Liang MG; Howard RM; McKee PH Am J Dermatopathol; 2003 Jun; 25(3):183-9. PubMed ID: 12775979 [TBL] [Abstract][Full Text] [Related]
3. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma. Khazaeli M; Grover R; Pei S J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731 [TBL] [Abstract][Full Text] [Related]
4. Symmetrical Skin Lesions on the Gluteal Region in a Patient with Anti-Laminin-332 Mucous Membrane Pemphigoid. Maki N; Demitsu T; Nagato H; Okada O; Yoneda K; Hashimoto T; Hasunuma N; Osada I; Manabe M Acta Dermatovenerol Croat; 2021 Jul; 29(2):105-107. PubMed ID: 34477077 [TBL] [Abstract][Full Text] [Related]
5. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia. Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447 [TBL] [Abstract][Full Text] [Related]
6. Linear IgA dermatosis with IgA and IgG autoantibodies to the 180 kDa bullous pemphigoid antigen (BP180): evidence for a distinct subtype. Metz BJ; Ruggeri SY; Hsu S; Reed JA; Ghohestani AS; Uitto J; Ghohestani RF Int J Dermatol; 2004 Jun; 43(6):443-6. PubMed ID: 15186228 [TBL] [Abstract][Full Text] [Related]
7. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid. Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473 [TBL] [Abstract][Full Text] [Related]
8. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum. Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183 [TBL] [Abstract][Full Text] [Related]
9. A Case of Possible Concurrence of Dermatitis Herpetiformis and Linear Immunoglobulin A / Immunoglobulin G Bullous Dermatosis. Minakawa S; Matsuzaki Y; Hashimoto T; Ishii N; Nishie W; Sawamura D Acta Dermatovenerol Croat; 2021 Jul; 29(2):116-117. PubMed ID: 34477081 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid. Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605 [TBL] [Abstract][Full Text] [Related]
11. A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens. Darling TN; Cardenas AA; Beard JS; Sau P; Yee CL; Zone JJ; Yancey KB Arch Dermatol; 1995 Dec; 131(12):1438-42. PubMed ID: 7492135 [TBL] [Abstract][Full Text] [Related]
12. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G Front Immunol; 2022; 13():984132. PubMed ID: 36189265 [TBL] [Abstract][Full Text] [Related]
13. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299 [TBL] [Abstract][Full Text] [Related]
14. [Subepidermal bullous autoimmune dermatosis with linear deposition of IgA amd IgG]. Kersting E; Goebeler M; Hamm H; Rose C; Zillikens D; Bröcker EB Hautarzt; 2000 May; 51(5):340-4. PubMed ID: 10875072 [TBL] [Abstract][Full Text] [Related]
15. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764 [TBL] [Abstract][Full Text] [Related]
16. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities. Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301 [TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid. Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P Front Immunol; 2019; 10():1934. PubMed ID: 31474998 [TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP. Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674 [TBL] [Abstract][Full Text] [Related]
19. Atypical Bullous Pemphigoid After Linagliptin Intake. Dbouk S; Bazzi N; Saad WA; Toribio A; Habre M; Salloum A Am J Case Rep; 2021 Sep; 22():e932356. PubMed ID: 34584063 [TBL] [Abstract][Full Text] [Related]
20. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease. Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]